ZEVRA THERAPEUTICS, INC. cotiza a 11.32 USD y tiene una capitalización bursátil de $672M. En los últimos 12 meses ha facturado $136M con un margen de flujo de caja libre del -2.3%. Cotiza a 20.6 veces su flujo de caja libre (P/FCF) y a un PER de 11.5. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical t…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.25 | $0.18 | $0.19 |
| Estimado | $0.18 | $0.18 | $0.08 | $0.05 |
| Sorpresa | — | +38.9% | +125.0% | +280.0% |
| Métrica | ZVRA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 84.5% | 57.0% | +27.5% |
| Operating Margin | -59.1% | -38.6% | -20.5% |
| Net Margin | 78.2% | -33.6% | +111.7% |
| FCF Margin | -2.3% | -13.9% | +11.6% |
| ROE | 53.8% | -40.4% | +94.2% |
| ROA | 29.2% | -32.0% | +61.2% |
| Current Ratio | 5.68 | 2.84 | +2.84 |
| Debt / Equity | 0.40 | 0.28 | +0.12 |